HC Wainwright Predicts Zynex's Q2 Earnings (NASDAQ:ZYXI)

Zynex, Inc. (NASDAQ:ZYXI - Free Report) - Equities research analysts at HC Wainwright cut their Q2 2025 earnings per share estimates for shares of Zynex in a report released on Wednesday, April 30th. HC Wainwright analyst Y. Chen now anticipates that the company will post earnings per share of ($0.20) for the quarter, down from their prior estimate of ($0.10). HC Wainwright has a "Buy" rating and a $8.00 price target on the stock. The consensus estimate for Zynex's current full-year earnings is $0.20 per share. HC Wainwright also issued estimates for Zynex's Q3 2025 earnings at ($0.20) EPS, Q4 2025 earnings at ($0.19) EPS, FY2025 earnings at ($0.92) EPS and FY2026 earnings at ($0.56) EPS.

Several other equities analysts also recently issued reports on ZYXI. Royal Bank of Canada cut their price objective on shares of Zynex from $5.00 to $4.00 and set a "sector perform" rating on the stock in a report on Wednesday, April 30th. LADENBURG THALM/SH SH cut shares of Zynex from a "buy" rating to a "neutral" rating in a report on Wednesday, March 12th.

Zynex Stock Down 1.2 %

Shares of NASDAQ ZYXI traded down $0.03 during mid-day trading on Friday, reaching $2.01. 48,516 shares of the company were exchanged, compared to its average volume of 158,004. Zynex has a 1 year low of $1.66 and a 1 year high of $11.14. The stock has a market cap of $60.63 million, a price-to-earnings ratio of 13.37 and a beta of 0.70. The company has a quick ratio of 3.15, a current ratio of 3.94 and a debt-to-equity ratio of 1.66. The firm has a 50-day moving average of $3.14 and a 200 day moving average of $6.38.

Zynex (NASDAQ:ZYXI - Get Free Report) last issued its quarterly earnings results on Monday, April 28th. The company reported ($0.33) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.09). Zynex had a net margin of 2.49% and a return on equity of 13.05%. The firm had revenue of $26.58 million for the quarter, compared to the consensus estimate of $30.83 million.

Institutional Trading of Zynex

Several institutional investors and hedge funds have recently bought and sold shares of the business. Geode Capital Management LLC boosted its stake in shares of Zynex by 4.1% in the fourth quarter. Geode Capital Management LLC now owns 443,020 shares of the company's stock valued at $3,549,000 after buying an additional 17,511 shares in the last quarter. Janney Montgomery Scott LLC raised its holdings in Zynex by 10.3% in the 4th quarter. Janney Montgomery Scott LLC now owns 159,259 shares of the company's stock valued at $1,276,000 after acquiring an additional 14,820 shares during the last quarter. Renaissance Technologies LLC boosted its stake in Zynex by 2.8% in the 4th quarter. Renaissance Technologies LLC now owns 137,362 shares of the company's stock worth $1,100,000 after buying an additional 3,800 shares during the last quarter. Congress Asset Management Co. increased its position in Zynex by 4.7% during the fourth quarter. Congress Asset Management Co. now owns 121,450 shares of the company's stock worth $973,000 after purchasing an additional 5,405 shares during the last quarter. Finally, Ameriprise Financial Inc. raised its position in shares of Zynex by 2.1% in the 4th quarter. Ameriprise Financial Inc. now owns 96,813 shares of the company's stock worth $775,000 after buying an additional 1,993 shares during the period. Hedge funds and other institutional investors own 29.68% of the company's stock.

Insider Activity at Zynex

In related news, CFO Daniel J. Moorhead sold 10,000 shares of the business's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $7.15, for a total transaction of $71,500.00. Following the completion of the transaction, the chief financial officer now owns 10,050 shares in the company, valued at approximately $71,857.50. The trade was a 49.88 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 49.28% of the stock is currently owned by company insiders.

Zynex Company Profile

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.